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Summary 
A double-blind study on 40 ambulant, 
mild to moderate hypertensive patients 
aged from 35-67 years showed that Bri-
nerdin is an effective anti-hypertensive 
ag,ent. After a dose-adjustment period and 
a 3-week wash-out the patients were ran-
domised into 2 groups each on active drug 
and placebo 'respectively. Regular physi-
cal and laboratory examinations were 
made. 
The Brinerdin group showed a highly 
significant fall in blood pressure. In all 
cas·es the fall was gradual without sudden 
fluctuation (see graph). By comparison 
the placebo group showed only insignifi-
cant changes in ·blood pressure. At the 
effective dosage of 1-3 tablets daily there 
were no untoward side-effects. As with all 
saluretic drugs some patients tended to 
hav.e slightly raised uric acid levels. 
Introduction 
Dihydroergocristine is a hydrogenated 
alkaloid of ergot. As such, it reduces vas-
cular tone through the vasomotor centre, 
exerts a peripheral adrenosympathicolyc-
tic action and has a mild central sedative 
effect. Clopamide is a salidiuretic. The 
propert:es of reserpine in producing a gra-
dual faH of blood pressure are well-known. 
Each tablet of Brinerdin contains: 
dihydroergocristine 
c~opamide 
reserpine 
0.5mg 
5.0mg 
O.lmg 
Objectives of the study 
The objectives of this study were: 
l. To evaluate the effect of Brlner-
din in reduc~ng blood pressure 
2. To determine its effects on sub-
jective symptoms of hypertension 
3. To confirm its safety by assess-
ment of the incidence and type of 
side effects and by laboratory 
investigations. 
Method 
A double-blind technique was employ-
ed using a preliminary adjastment period. 
40 ambulant patients suffering from mild 
to moderate hypertension were selected 
for the study. Of these, 32 completed the 
study within the date-line set for evalua-
tion. 3 patients dropped out during the 
trial. 
The remaining 8 patients finished the 
trial later but the computerised progr.am-
ming for evaluation had already been com-
pleted. Analysis of the additional data 
showed a decrease of 5Q% on values above 
not in any way alter the overall results 
of the trial. 
Adjustment period 
During the first 4 weeks of the study 
patients were given increasing doses of 
Brinerdine until the effective dose for each 
patient was determined. For the purpose 
of the trial an effective lowering of the 
blood pressure was considered to have 
been achieved when the diastoHc pressure 
showed 'a decrease of 5% on values above 
90mm.Hg. There were 2 drop outs during 
this period. 
Wash-out period 
The period of adjustment was follow-
ed by a wash-out phase of 3 weeks during 
wh'ch aell pa'tients received placebo. 
Duuble-blind period 
FinaHy the patients were randomised 
into 2 equal groups of 15 patients each 
taking active drug and placebo respec-
tively for 6 weeks. The third drop-out 
from the group on active drug occurred 
during this phase. 
Evaluations 
Throughout the study blood pressure 
readings were taken at weekly intervals 
in the st8Jnding, s,itting and supine posi-
tions. The values recorded in each case 
were the mean of 2 separate readings. The 
same technique was applied in reading the 
pulse rate. 
Accompanying symptoms of hyper-
tension - such as headache, dyspnoea, 
dizziness and vertigo, insomnia, fatigue, 
anxiety and depression - were evaluated. 
In order to, determine whether Brinerdin 
causes any biochemical disturbances the 
following laboratory investiga,tions were 
carried out at the beginning and end of the 
adjustment period after 3 weeks of the 
double-blind phase and at the end of the 
trial: 
l. 
2. 
3. 
4. 
5. 
6. 
Haemoglobin estimation 
Full blood count 
Blood urea 
Serum electrolytes (sodium, 
tassium and chlorides) 
Blood cholesterol 
Urdc acid. 
Results 
po-
Of the 29 patients evaluated statisti-
tically 14 had been p~aced on Brinerdin 
during the double-blind phase while 15 
received placebo. 
The Brinerdin group consisted of one 
patient who was classified a severe hyper-
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tens,ive, 8 who had moderate hypertension 
and 5 with mild hypertension. In the pla-
cebo group 7 were classified as moderate 
hypertensives and 8 as mild hypertensives. 
There were no patients with renal compli-
cations in either group. The duration of 
the condition varied from 0-8 years with a 
mean of 3 years. Ages ranged from 35-67 
and there was a family history of hyper-
tension in 10 cases. The effective dose of 
Brinerdin established during the inWal 
adjustment period varied from 1-3 tablets 
per day. 
Adjustment period 
During th!s period a highly ,significant 
lowering of blood pressure was achieved 
(p<O.OOI). The mean fall in systolic pres-
sure was 35mm.Hg. while the mean fall 
in diastolic pressure was 19mm.Hg. 2 pa-
tients were taken off Brinerdin early 
during this period. One patient was proved 
to have had a myocardial infarction prior 
to starting treatment with Brinerdine. 
Another patient, who suffered for many 
years with chronic diarrhoea from ulcera-
rve colitis complained of coldness and 
dizziness a,fter taking the tablet 
Wash-out period 
During the wash-out period blood 
pressure readings showed a significant rise 
(p<O.OOI) towards previous levels. At the 
end of this phase the mean systolic pres-
sure had ris-en by 29mm.Hg. and the mean 
diastolic pressure showed an increase of 
16mm.Hg. 
Double-blind period 
One patient in the Brinerdin group 
dropped out of this phase because of epi-
gastric pain. However this pain had per-
sisted during the placebo wash-out period 
and was later proved to be due to chole-
cvstitis 
" Th~ 14 patients on Brinerdin again 
showed a highly significant f'all in blood 
pressure. From a mean value of 
184.3/110.7/mm.Hg. in the sitting position 
at the end of the wash-out period readings 
fell to a mean of 149.3/96mm.Hg. This 
fall becomes even more significant when 
the values reached at the end of the trial 
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are compared w1th those found when the 
study began. The mean value recorded in 
both groups at the initiation of the trial 
and at the end of each phase are to be 
found in the folloWiing table. 
In all cases in the Br.inerdin group 
the f·aH in blood pressure during the 
double-blind phase was gradua.l without 
the objective finding,s and the subjective 
assessment by the physician. 
Side effects 
The 3 drop-outs in the trial have al-
ready been described. 
During the entire duration of 'the trial 
other side effects encountered were sh9rt-
Mean Blood Pressure Readings in Sitting Position (mm.Hg.) 
Initiation End of End of End of 
Group lof trial adjustment wash-out do ub le~blind 
period period period 
Brinerdin 189.67/114.67 150/93.67 184.33/110.67 149.27/96.06 
Placebo 184.67/110.67 157/92.67 172.67/107.67 168.4/105.8 
any ma,rked fluctuations (see graph). By 
companison the 15 patIents who received 
placebo during this phase of the trial 
showed only insignificant changes in blood 
pressure. 
The pulse rate observations dur-
ing the study showed no appreciable 
change and the accompanying symptoms 
of hypertension ·were too mild and infre-
quent to be evaluated. 
There was good correlation between 
Blood pressure 
(standing) 
lived and never severe enough to stop me-
dication. 
Ten pa·tients taking Br.inerdin show-
ed elevated uric acid levels at the end of 
the study. The mean value for this group 
rose from 4.98mg/100ml (3.2-8.0) at the 
beginning of ,the trial to 6.29mg/100ml 
(4.4-11.2) at the lOth week. 
'In the placebo group 6 patients also 
finished the study with high uric acid 
levels. 
Blood pressure 
(supine) 
............. ,#' .......... - .... '-0 .. PLA 
mmHg 
W9 
180 
170 
160 
150 
140 
130 
120 
110 
100 
........... ~" ....... _ ....... w ........... PLA 
90 
80 
70 
60 
OCR 
jDCR lwash i 1 2 3 4 5 6 weekS Dosage out double-blind period 
adjustment period 
period 
OCR 
.................. · .......... ....,... ........ PLA 
.... 
... OCR 
Dosage ~~s double-[lllnd period iDeR 1 h i 1 2 3 4' 5 6 weeks adjustment period 
period 
AB the other laboratory values inves-
tigated remained within physiological 
Hm'ts for all patients. No hypokalaemia 
was observed. 
Conclusion 
The study demonstrates that at a 
dosage of 1-3 tablets per day Brinerdin 
is an effective anti-hypertensive agent. In 
all cases comparison with placebo showed 
a highly significant difference in favour of 
Brinerdin. Subjective side effects show a 
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low :.ncidence and are not of a serious na-
ture. Thele is, however, a tendency to-
wards the production of raised uric acid 
levels but this is a known consequence of 
saluretic drugs. 
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Introduction 
In Malta pulmonary tuberculosis as 
such was included in the Schedule of 
notifiaJble diseases in 1908. For some 
inexplici:1ble reason, it was only 40 years 
later that other forms of tuberoulosis 
became notifiable by law. 
A government hospital for pulmonary 
tuberoulosis existed since the beginning 
of this century, but it was in 1948 that a 
proper "contact" clinic w~s established 
for the ·first time and methods of control 
of ,the disease set on a sound bas'is. In 
1950, under the auspices of the Inter-
national Tuberculosis Campaign, an expert 
medical and para-medical team from 
Norway to.gether with four Maltese teams 
carried out a Tuberculin Survey of a 
section of the population, mostly persons 
aged 1-18 years, and vaccinated with 
B.c.G. the negative reactors. (Report on 
the Health Conditions of the Maltese 
Islands, 1950; Zammit Tabona, 1952). 
S:nce then, Tuberculin testing and B.C.G. 
vaccination have been carried out routine-
ly in school-children (in 12-14 years old 
only since 1960) as a yearly campa'ign, as 
well as ,in oontacts and in persons at risk 
of infection. 
All anti-tuberculosis drugs have been 
available JocaHy at all times and in 
sufficient quantities. Treatment in and out 
of hospital as weIl as supplies of drugs are 
given free to tuberculosis patients and 
thek famiEes at Government expense. and 
a grant to a max1mum of about £M12 
monthly, is allowed provided that both the 
patient and members of the same house-
hold caB regularly for supervision of treat-
ment and for periodical examination. 
Tt is relev,ant to note that the Maltese 
